Seagen Strikes $2.6B ADC Deal with China’s RemeGen

Last week, Seagen, a Washington-based biotech company, announced a deal with China-based RemeGen Co., Ltd. The deal, valued at $2.6B, allows Seagen to develop disitamab vedotin, a novel HER2-targeted antibody drug conjugate (ADC).

“The addition of disitamab vedotin as a late-stage asset with multiple development opportunities aligns strategically with our plans to continue expanding our global footprint and deliver meaningful therapies to patients around the world,” said Clay Siegall, President and CEO of Seagen.